Ribonucleic acid (RNA) therapeutics developer Atrium Therapeutics Inc (Nasdaq:RNA) announced on Monday the award of inducement grants under its 2026 Employment Inducement Incentive Award Plan as a material inducement to the employment of seven non-executive individuals newly hired by the company.

The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of Atrium Therapeutics' common stock, par value USD0.001 per share, with an exercise price of USD14.30 per share, the closing price of the company's common stock as reported by Nasdaq on the effective date of the grant. Of these, 25% will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal instalments each month thereafter, subject to the employee's continued service with the company through each applicable vesting date.

Atrium Therapeutics also awarded restricted stock units for an aggregate of 50,625 shares of its common stock, 25% of which will vest on the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal instalments each year thereafter, subject to the employee's continued service with the company through each applicable vesting date.

These awards were granted outside the company's stockholder-approved equity incentive plans pursuant to the 2026 inducement plan, which was adopted by the board of directors in April 2026. The awards were approved by the board's Human Capital Management Committee, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).